
    
      This is an Open-label, randomized, 2-way cross-over, Phase I study. The study is conducted in
      1 single european site. The main scope of the study is to compare the systemic availability
      to CHF 6001 after a single dose of CHF 6001 DPI administered using the multi-dose reservoir
      NEXThaler® device or the single-dose capsule Aerolizer® device.
    
  